Horobin Joanna 4
4 · Kymera Therapeutics, Inc. · Filed Jun 7, 2024
Insider Transaction Report
Form 4
Horobin Joanna
Director
Transactions
- Sale
Common Stock
2024-06-07$33.11/sh−6,313$209,005→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-06-07−8,500→ 33,195 totalExercise: $2.08Exp: 2029-05-22→ Common Stock (8,500 underlying) - Exercise/Conversion
Common Stock
2024-06-07$2.08/sh+8,500$17,680→ 8,500 total - Sale
Common Stock
2024-06-07$32.65/sh−2,187$71,395→ 6,313 total
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 8, 2024 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.88 to $32.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.88 to $33.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of May 16, 2018, subject to the reporting person's continued employment through each vesting date.